Table 2 Baseline characteristics of the studies included in this review
Studies | Country | Study design | Year of publication | Baseline comparison (Y/N) | Number of participants (TFL) | Mean age (years) | Follow-up |
|---|---|---|---|---|---|---|---|
Delbarre et al. [10] | France | Prospective study | 2023 | Yes | 100 | 60.1 ± 17.7 | 3 months |
Singh A et al. [11] | India | Prospective clinical trial | 2023 | NR | 76 | NR | NR |
Quiroz Madarriaga Y. et al. [12] | Europe and Asia | Prospective clinical trial | 2023 | NR | 40 | 8.5 | NR |
Geavlete B. et al. [13] | Romania | Retrospective study | 2022 | Yes | 59 | 48.94 ± 15.93 | 3 months |
Soundarya G. et al. [14] | India | Prospective clinical trial | 2022 | NR | 52 | 40.91 ± 12.62 | 5.98 ± 0.79 months |
Sytnik D. et al. [15] | Russia | Prospective clinical trial | 2022 | Yes | 12 | NR | Â |
Taraktin M. et al. [4] | Russia | Prospective Clinical study | 2022 | Yes | 153 | 54 ± 2.8 | 3 months |
Vaddi C.M. et al. [16] | US | Prospective study | 2022 | Yes | 126 | 45.04 ± 12.30 | 3 months |
Sierra et al. [17] | Japan | Prospective study | 2021 | Yes | 50 | 55(44–61.5) | NR |
Taraktin M. et al. [18] | Russia | Retrospective study | 2021 | NR | 14 | NR | 3Â months |
Enikeev D. et al. [19] | Russia | Prospective study | 2020 | Yes | 40 | 56 | 3Â months |
Korolev D. et al. [20] | Russia | Clinical study | 2020 | NR | 130 | NR | NR |